Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Immunosuppressive drug Stories

2012-09-18 06:29:02

DPC Urges Swift Passage of Bill to Extend Drug Coverage for Transplant Patients WASHINGTON, Sept. 18, 2012 /PRNewswire-USNewswire/ -- Data from a recent survey of Dialysis Patient Citizens' (DPC) kidney disease patient membership highlights the strong need for swift Congressional action on the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011 (H.R. 2969/S.1454). The survey data released today reinforces concerns that many dialysis patients are not...

2012-09-04 02:28:54

PRINCETON, N.J., Sept. 4, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the National Cancer Institute (NCI) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec® (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal (GI) manifestation of chronic...

2012-06-14 02:25:00

CHILLY-MAZARIN, France, June 14, 2012 /PRNewswire/ -- InGen BioSciences, specialised in the development and commercialisation of mono and multiparametric in vitro diagnostic tests announced a new exclusive partnership with Cylex Incorporated (Columbia, Maryland,...

2012-03-28 00:18:58

New publication outlines management strategies to prevent bone loss and related fractures in high-risk patients Oral glucocorticoids are commonly prescribed for a wide variety of disorders, most commonly for rheumatoid arthritis, obstructive pulmonary disease and inflammatory bowel diseases. However, the use of these medications can result in rapid bone loss during the first three to six months of therapy, leading to increased risk of fragility fractures. Although awareness of...

2012-02-13 08:00:00

ABBOTT PARK, Ill., Feb. 13, 2012 /PRNewswire/ -- A new study published in the journal Clinical Chemistry reported Abbott's (NYSE: ABT) ARCHITECT® Tacrolimus assay provides accurate and consistent medication monitoring for patients taking tacrolimus, an immunosuppressive medication, after receiving solid organ transplantation. Tacrolimus is a calcineurin inhibitor often used in patients to help prevent organ rejection. For continued organ survival, a transplant patient must be...

2012-01-27 11:24:48

Stopping immunosuppressive prednisone soon after transplantation found safe Highlights:     Patients who quickly stop taking the immunosuppressant prednisone after receiving a kidney transplant avoid experiencing serious prednisone-related side effects.     This rapid discontinuation of prednisone does not jeopardize the long-term survival of patients and their new organs.     Approximately 16,500 patients receive kidney transplants each...

2011-12-12 22:25:37

Transplant surgeons live in the hope that one day they will be able to wean at least some of their patients off the immunosuppressive drugs that must be taken to prevent rejection of a transplanted organ. A team of researchers led by Alberto Sánchez-Fueyo, at the University of Barcelona, Spain, has now identified markers that might make this possible for liver transplant recipients. Transplant recipients must take immunosuppressive drugs for the rest of their lives to prevent...

2011-12-12 06:00:00

PRINCETON, N.J., Dec. 12, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec® for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell...

2011-11-17 10:16:14

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis. "This is a huge step forward for people who suffer from lupus nephritis," said Mary Anne Dooley, MD, MPH, associate professor in the University of North Carolina at Chapel Hill School of Medicine and first author of the study, which is published in the Nov. 17, 2011 issue of the New England...

2011-10-06 09:13:12

Investigators at the Stanford University School of Medicine have developed a novel protocol that allows kidney-transplant recipients to jettison their indispensable immune-suppressing drugs. The protocol could also spell substantial savings to the health-care system. The researchers have reported their progress in a letter that will be published Oct. 6 in the New England Journal of Medicine. Eight of the 12 patients discussed in the small study have now been off of immunosuppressant drugs...